Following a pre-maturation phase, the “MucoLip” project (Project leaders: Françoise Pons & Luc Lebeau) entered in a maturation phase (funding from SATT Conectus Alsace). This project aims to develop auxiliary lipids to confer intrinsic mucolytic activity to lipidic nanoparticles for the release of therapeutic nucleic acids during mucosal administration by increasing the efficiency of transfection. This strategy is developed to treat, locally, pulmonary diseases such as cystic fibrosis, chronic obstructive pulmonary disease (smoker's disease), asthma or certain lung cancers.
